Follow us on Twitter
twitter icon@FreshPatents


Diabetes patents

      

This page is updated frequently with new Diabetes-related patent applications.

SALE: 520+ Diabetes-related patent PDFs



new patent Intrinsic chromosomal linkage and disease prediction
An improved method is the product of an exploration for ways in which to improve the success of genomic disease prediction and presents the elements of more successful prediction tools for the identification of genomic locations of disease based on: genomic labeling it loci as determined by correlated snp linkage as determined from several additional gwas (genome wide association studies) databases. The wellcome trust t2d (type 2, adult-onset, diabetes) has played a particularly important role in developing the new tools; additionally, the development of a wellness classifier, probably in part due to counter disease mutations has proven to be a powerful new tool and concept.

new patent Use of mip-1beta inhibitors for improving angiogenesis to reduce tissue ischemia and rescue diabetic vascular disease in diabetes mellitus
The present invention relates to a use of mip-1β inhibitor for promoting angiogenesis in diabetes mellitus patients so as to improve tissue ischemia in damaged area and to prevent diabetic vasculopathy.. .
National Yang-ming University Taipei Veternas General Hospital


new patent Substituted bridged urea analogs as sirtuin modulators
Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc


new patent Compositions and methods for treating retinal degradation
The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by alu rna associated with a cell, for reducing atp-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an rpe cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (amd) and wet amd, alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and duchenne muscular dystrophy..
University Of Kentucky Research Foundation


new patent Vascular calcification prevention and treatment
The invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (vsmcs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (vc) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.
Summit Innovation Labs Llc


new patent Metabolic syndrome treatment
Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc


new patent Treatment and prevention of diabetes and obesity
Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.. .

Genetically modified mesenchymal stem cell expressing klotho
A genetically modified mesenchymal stem cell (msc) includes an exogenous nucleic acid that includes a klotho encoding region operably linked to a promoter or promoter/enhancer combination. The mscs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as alzheimer's disease (ad), multiple sclerosis (ms), huntington's disease, amyotrophic lateral sclerosis (als), parkinson's disease, and schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases..
Apceth Gmbh & Co. Kg


Fiber-rich maltooligosaccharides having low glucose bioavailability, manufacture thereof and use thereof in human food and animal feed
The present invention relates to maltooligosaccharides, the content of α-1,4-glycosidic bonds of which is between 70% and 80% of the total number of 1,4-type glycosidic bonds. The invention also relates to the method for manufacturing these maltooligosaccharides.
Roquette Freres


Substituted quinolines as pde-10 inhibitors
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.


Compounds and methods for inducing browning of white adipose tissue

The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula i, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes..
Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences

Dermatopontin as a therapeutic for metabolic disorders

The present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type i diabetes, type if diabetes and cardiovascular disease. Disclosed herein is also a method of determining or making a prognosis of a subject's susceptibility to metabolic diseases and obesity, the method comprising measuring the level of circulating dermatopontin in a sample obtained from a subject; and comparing the level of circulating dermatopontin obtained with the level of dermatopontin previously determined in a control; and determining the susceptibility of the subject to metabolic disease and obesity based on the difference between the level of circulating dermatopontin and the level of dermatopontin in the control..
Agency For Science, Technology And Research

Method for treating hiv

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones.
Enzo Therapeutics, Inc.

A protecting against carbonyl stress induced ischemia-reperfusion injury in the diabetic brain via administration of n-acetylcysteine

A method for one of preventing and minimizing diabetes pathology in a mammal, comprising administering to the mammal an effective amount of n-acetylcysteine (nac).. .
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

No donors for the treatment of impaired tissue perfusion

A method for treatment of prophylaxis of a chronic disease or condition associated with impaired tissue or organ perfusion, comprising administering an amino-c2-c6-alkyl nitrate, an amino-c2-c4-alkyl nitrate, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. The disease or condition is a micro- and/or macro-vascular disease selected from the group of diseases associated with impaired capillary function, impaired muscular function, impaired skin function, impaired cartilage function, impaired myocardial function, impaired retinal function or impaired organ function caused by impairment of tissue and organ perfusion or by impairment of the regeneration of capillaries, arterioles or other vascular tissue.
Mirandapharmaceuticals Ag

Active substances and cosmetic or dermatological preparations containing said active substances for the care of the skin of patients of diabetes mellitus

Licochalcone a and/or plant extracts or microbiologically obtained extracts with an active content of licochalcone a or cosmetic or dermatological preparations containing licochalcone a and/or plant extracts or microbiologically obtained extracts with an active content of licochalcone a for the care of the skin of patients of diabetes mellitus.. .
Beiersdorf Ag

Aptamers and sensing technology used for detection of glycated hemoglobin in whole blood

High affinity dna aptamers seq id#1-8 for hba1c and thb were successfully selected using selex after 11 rounds of selection. The tested aptamers bind to hba1c with dissociation constants in the nanomolar range with the highest affinity aptamer, seq id#6, exhibiting a kd of 2.8 nm.
Alfaisal University

Devices for detection of antibodies against therapeutic drugs

Devices for detection of antibodies against therapeutic drugs (adas), in which chimeric proteins facilitate immobilization and exposure of target epitopes, are described. Results can be obtained in minutes, enabling point of care testing and/or patient self-testing, and risk assessment.

Devices, solutions and methods for sample collection related applications, analysis and diagnosis

A solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. Saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition.
Abogen, Inc.

Diagnostic methods, therapeutic agents and uses thereof

The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (vi): or a salt thereof.
Metabolon, Inc.

Puma, a pro-apoptotic gene, as a novel molecular biomarker for tnfalpha-induced human islet damage

P53-upregulated modulator of apoptosis (puma) is a biomarker associated with islet cell health. If puma is low, islet cells are typically healthy.
Hitachi Chemical Co., Ltd.

Compositions and methods for treating fatty tissue buildup

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Apelin fusion proteins and uses thereof

The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.

Crystal form a of compound and preparation method thereof

The present invention relates to crystal form a of a compound. The present invention also discloses a preparation method and a pharmaceutical composition of the crystal form a.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Compounds and methods to suppress autoimmune response

A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (ahr) ligand. The ahr ligand includes 11-cl-bbq, 10-cl-bbq, an analog of 11-cl-bbq, or combination thereof.
Oregon State University

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases..
University Of Southern California

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Compositions and methods for treating obesity and hyperphagia

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as prader-willi syndrome, obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes

The present disclosure describes a genome-wide transcriptional analysis of differentially expressed genes in diabetic, non-diabetic, normal and wounded tissue. The analysis allowed development of compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes, including delayed wound healing and reduced vision..
Wayne State University

Methods of preventing the occurrence of cardiovascular events

The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events..
Kowa Company, Ltd.

Methods of preventing cardiovascular events in residual risk dyslipidemic populations

The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled ldl-c concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled ldl-c..
Kowa Company, Ltd.

New azabenzimidazole derivatives as agonists of the amp-activated protein kinase

The present invention relates to compounds of general formula i, wherein the group r1, x and y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh

Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes

The invention relates to biomarkers associated with diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop diabetes, and methods of screening a population to identify persons at risk for developing diabetes and other pre-diabetic conditions.. .
True Health Ip Llc

Oligonucleotide sequences targeting transcription factortsc22d4 for the treatment of insulin resistance

The present invention relates to oligonucleotide inhibitors of the tsc22d4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.. .
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Glucagon antagonists

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Probes and methods for detecting amyloidogenic proteins

Disclosed herein are novel photocontrollable probes and methods for detecting aggregated forms of amyloidogenic proteins in cells, tissues, or organs of a live subject. Results of such detection may be useful for making prognosis on the subject whether he/she suffers from a neurodegenerative disease and/or diabetes mellitus..
Academia Sinica

Nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine

Nutritional products, compositions, pharmaceutical preparations and methods of use are disclosed for the prevention, suppression and treatment of anemia and/or diabetes and its various associated comorbidities. Uses of ergothioneine to neutralize free radicals and/or cytokines, reduce oxidative stress, prevent inflammation, stimulate red blood cell production with increased levels of hemoglobin, and/or stabilize iron in its normal 2+ charge for proper oxygen binding and carrying are further disclosed.
Entia Biosciences, Inc.

Bifidobacteria for treating diabetes and related conditions

This invention relates to new uses of bifidobacteria (particularly, although not exclusively, probiotic bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions..
Dupont Nutrition Biosciences Aps

Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

Compounds and methods are provided for the treatment of, inter alia, type ii diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active..
Cymabay Therapeutics, Inc.

Flip - a selective molecular target of senescent cells

The present invention relates to modulators of flip protein and their method of use in the treatment and prevention of diseases and pathologies related to accumulation of senescent cells during aging, such as cancer, chronic obstructive pulmonary disease (copd), osteoarthritis, atherosclerosis, neurodegenerative diseases, diabetes, and many others. The present invention also relates to pharmaceutical compositions containing these compounds as well as various uses thereof..
Bioventures, Llc

Compositions comprising beta-hydroxybutyric acid and salt, and methods of using the same

β-hydroxybutyric acid in combination with β-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/l), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of β-hydroxybutyric acid and salt results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time.
Savind, Inc.

Method, system and computer readable medium for assessing actionable glycemic risk

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (cgm) data.. .
University Of Virginia Patent Foundation

Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs

Ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and/or tissue. A patient suffering from disease caused in at least some part by ischemia is selected.

Acylated glucagon analogues

The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral ph, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Wherein the x1 denotes that the i residue is modified by either acetylation or methylation at the n-terminus; wherein x2 is l or t; wherein x3 is l or i; wherein x4 is q or e; and wherein a modified k residue (“k*”) at position 29 is modified through conjugation to the epsilon-amino group of the k-side chain with a group of the formula —x5—x6, wherein x5 is selected from the group consisting of one to four amino acids; one to four ([2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties; and combinations of one to four amino acids and one to four ([2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties; and x6 is a c14-c24 fatty acid. In some embodiments, the group of the formula —x5—x6 is ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γe)2-co—(ch2)x—co2h where x is 16 or 18..

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue, in embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms..
Neurotronic, Inc.

Therapeutic homodimer and uses thereof

The invention relates to therapeutic peptides and uses thereof. In particular, the invention relates to disulphide-linked homodimers useful in the treatment or prevention of diseases and conditions in mammalian subjects (such as diabetes), via transmucosal administration..

Modulators of alpha-dicarbonyl detoxification and their use for the treatment of diabetic pathologies

In various embodiments compositions and methods are provided for ameliorating a pathology characterized by elevated α-dicarbonyl compounds or prophylactically slowing or stopping the onset of said pathology in a mammal. In certain embodiments the method comprises administering to the mammal an agent that activates trpa1 in an amount sufficient to activate trpa1, and/or to ameliorate one or more symptoms of the pathology (e.g., diabetes or a complication thereof), and/or to slow or stop the onset of the pathology, and/or to lower the level of α-dicarbonyl compounds in the mammal..
Buck Institute For Research On Aging

Devices and methods for managing insulin resistance

Disclosed are devices and methods for mitigating insulin resistance in a human subject by contacting one or more regions of the neck, the supraclavicular, and the interscapular regions of the human subject with a part of a cooling device, wherein the part of the cooling device has a temperature at about 15 or less celsius degrees; cooling the one or more regions of the neck, the supraclavicular, and the interscapular regions of the human subject for a cooling period of at least 15 minutes; and performing previous two steps daily for about 14 or more days. The devices and methods may also be used to preventing, delaying or treating type 2 diabetes in a human subject or activating brown fat without incurring a sympathetic nerve-mediated cold feeling in a human subject..
Gludone Inc.

Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof

The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof.
University Of Technology, Sydney

Glucagon-receptor selective polypeptides and methods of use thereof

This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon.
Intarcia Therapeutics Inc.

Compositions and methods of using islet neogenesis peptides and analogs thereof

The invention provides peptides and analogs of ingap and hip peptides. The peptides and analogs can be used in methods for treating various diseases and conditions.
Shenzhen Hightide Biopharmaceutical, Ltd.

Method for preparing nanoprecipitates of low molecular weight peptide or protein

The present invention relates to a method for the non-denaturing preparation of peptide or protein nanoprecipitates, or of peptide or protein and metal ion nanocoprecipitales, in which said protein or said peptide has a molecular weight no higher than 20 kda, preferably no higher than 15 kda, advantageously no higher than 10 kda, and more advantageously no higher than 8 kda. Said method includes a step of preparing a mixture of an aqueous solution of peptides or proteins, a nonsolvent of the peptide or protein, and optionally a water-soluble metal salt.
Carlina Technologies

Isoquinoline derivatives as mgat2 inhibitors

The compounds of formula i act as mgat2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.. .
Merck Sharp & Dohme Corp.

Chromenone inhibitors of monocarboxylate transporters

The invention provides compounds effective as inhibitors of monocarboxylate transporters such as mct1 and mct4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on mct1, mct4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type ii diabetes..
The Scripps Research Institute

Indication mechanism for an automatic applicator, particularly for insulin

The present disclosure concerns an indication mechanism for an automatic applicator, particularly for insulin or other liquid preparations, particularly for multiple injection administration of set doses of a medicine from an exchangeable container, for example for the self-application of insulin by diabetes patients. An indication mechanism for an automatic applicator, having an assembly of at least two barrels movably coupled to each other has an indication barrel mounted on the driving barrel contains only marking on its external surface and is co-axially connected to the pull-push control nut..
Copernicus Sp. Z O.o.

Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1)

Disclosed are compositions and methods for inducing sustained diabetes remission by single administration of fgf1 to the brain. The composition and methods described herein result in basal glucose clearance by using a dosage of fgf1 that is lower than that needed for systemic efficacy and is devoid of the risk of hypoglycemia and changes in body weight, food intake, hepatic glucose production, insulin secretion or insulin sensitivity..
University Of Washington

Health care

The treatment of type 2 diabetes involving the use of a regimen comprising: (a) one or more glucose-lowering drugs (g-lds) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (b) at least one non-steroidal anti-inflammatory drug (nsaid) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “mg salicylate”); (2) naproxen; and (3) ibuprofen; and (c) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (b) and (c) above..

Pteridine dione monocarboxylate transporter inhibitors

The invention provides compounds effective as inhibitors of monocarboxylate transporters such as mct1 and mct4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on mct1, mct4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type ii diabetes..
The Scripps Research Institute

Medical condition management system and methods

A system ranks pharmaceutical and other regimens for the treatment of chronic diseases (e.g., diabetes) to optimize the patient, medical, financial, and operational aspects of drug therapy using a combination of data impossible for a human to consume and process within any useful period of time. A scoring algorithm balances estimated cost, intolerance, benefit, and efficacy, using information from the patient's medical history, personal preference, drug manufacturers, clinical trial data, and other sources (e.g., insurance payment data) for every possible therapy and combination of therapies.

Metabolite biomarkers predictive of renal disease in diabetic patients

The present invention relates to biomarkers that are predictive of renal disease in patients who have diabetes. The present invention also provides methods of using such biomarkers to predict the risk that a diabetic patient will develop renal disease, and/or to identify a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease..
Joslin Diabetes Center

Fas and drs are novel molecular targets of senescent cells

The present invention relates to modulators of fas and drs and their method of use in the treatment and prevention of diseases and pathologies related to accumulation of senescent cells during aging, such as cancer, chronic obstructive pulmonary disease (copd), osteoarthritis, atherosclerosis, neurodegenerative diseases, diabetes, and many others. The present invention also relates to pharmaceutical compositions containing these compounds as well as various uses thereof..
Bioventures, Llc

New azabenzimidazole derivatives

The present invention relates to compounds of general formula (i), wherein r1, r2, r3, a1, a2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh

Heterocyclic inhibitors of monocarboxylate transporters

The invention provides compounds that inhibit monocarboxylate transporters, such as mct1 and mct4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of mct1 and/or mct4, such as cancer or type ii diabetes..
The Scripps Research Institute

Ethynyl derivatives

The present invention relates to compounds that may be used for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.

Dry powder drug delivery system and methods

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity..
Mannkind Corporation

Stable pharmaceutical solution formulation of glp-1r antibody fusion protein

Disclosed is a stable pharmaceutical solution formulation of a glp-1r antibody fusion protein, comprising a therapeutically effective amount of the glp-1r antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mm, the final concentration of the surfactant is 0.01%-0.5%, and the ph value of the stable solution formulation is from 5.0 to 8.0.
Gmax Biopharm Llc.

Prevention of hypoglycaemia in diabetes mellitus type 2 patients

A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) despro36exendin-4(1-39)-lys6-nh2 or/and a pharmaceutically acceptable salt thereof, and (b) a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.. .
Sanofi-aventis Deutschland Gmbh

Method of treating or ameliorating type 1 diabetes using fgf21

Methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease.
Amgen Inc.

Disease prevention and alleviation by human myoblast transplantation

Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways.

Modified release compositions of epalrestat or a derivative thereof and methods for using the same

Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided..
Bionevia Pharmaceuticals Inc.

Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions

Disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (lada) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid x receptor (fxr) agonist compounds, thereby activating fxr receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (lada) in the subject..
Salk Institute For Biological Studies

1,3-substituted 2-amino-indole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity, and inflammatory bowel disease

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein q, x4, x5, x6, x7, r1, r2, r3 and r8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.. .
Takeda Pharmaceutical Company Limited

Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof

Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.. .
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Method for treatment of hyperglycemia and hyperlipidemia

Provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin k. Also provided is a method of enhancing protein expression ratio of phospho-5′ adenosine monophosphate-activated protein kinase (phospho-ampk) to total ampk in skeletal muscle or liver of a subject, and a method of reducing blood leptin in a subject.

Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.. .
Boehringer Ingelheim International Gmbh

Fusion polypeptide containing glp and immunoglobulin hybrid fc and use thereof

The present invention relates to a fusion polypeptide containing a glucagon-like peptide (glp) and an immunoglobulin hybrid fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid fc suitable for glp or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to dpp-4 enzyme compared to those of glp-1 and glp-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs.
Genexine, Inc.

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Bicyclic compounds, compositions and medicinal applications thereof

These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (rorγ) such as inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, copd, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, erythematosus or other disorders.. .

2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase

Wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as alzheimer's disease (ad), mild cognitive impairment, senility, dementia, dementia with lewy bodies, down's syndrome, dementia associated with stroke, dementia associated with parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes or metabolic disorders..

Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes

Wherein r1, r2, r3, r5, r6, w, and a are defined herein.. .

Co-agonists of the glucagon and glp-1 receptors

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 receptor/gcg receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), and obesity. .
Merck Sharp & Dohme Corp.

Methods for the treatment of polycystic ovary syndrome

Polycystic ovary syndrome (pcos) is a complex and heterogeneous endocrine syndrome associated with a high risk for the development of insulin resistance, type 2 diabetes (t2d), obesity, dyslipidemia, and cardiovascular disease. There are no known therapies for the 9-18% of women afflicted with pcos.
Center For Reproducitive Medicine, Shandong Provincial Hospital, Shandong University

Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies

The present invention relates to tolerogenic mammalian dendritic cells (idcs) and methods for the production of tolerogenic dcs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Compositions and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Procedure for the acquisition of data for the detection of angiogenesis in lower limbs

The invention relates to a method for obtaining useful data about the angiogenesis in a patient's lower limbs, and particularly in the lower limbs of patients with diabetes subjected to treatment.. .
Universidad De Córdoba

Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays

This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
Senomyx, Inc.

Methods of reprogramming cells

The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics.
President And Fellows Of Harvard College

Method of isolating cells from a tissue in a mammal

Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer.
The Board Of Trustees Of The University Of Illinois

Peptides for modulating t-cell activity and uses therof

The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with cd40, thereby interfering with the ability of cd40 to interact with cd154, which is important in inflammation.
The Regents Of The University Of Colorado, A Body Corporate

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

Fibronectin based scaffold domain proteins that bind to myostatin

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company

Anti-obesity and anti-diabetic effects of angiopoietin-like 4 (angptl4) fibrinogen-like domain

Angiopoietin-like 4 (angpt14) is a secreted protein that inhibits lipoprotein lipase (lpl) activity and promotes lipolysis in adipocytes. The present methods provides compositions comprising angptl4 fld and variants thereof of methods of using such compositions to protect a subject diet-induced obesity without affecting plasma tg levels, and, in an exemplary emobiment improve glucose homeostasis.
The Regents Of The University Of Califorina

Co-encapsulation of live cells with oxygen-generating particles

Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described..
Wake Forest University Health Sciences

Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin.
Vtv Therapeutics Llc

Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome

The disclosure provides thiol-containing alkyl fatty acid and vitamin d compound formulations for intravenous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are useful for treating metabolic dysfunctions such as pre-diabetes, metabolic syndrome and diabetes.

Pairing and synchronizing a mobile phone application with a handheld glucose meter

A diabetes management system includes a handheld medical device, a mobile computing device, and a diabetes management application. The handheld medical device is configured to determine, in response to a port receiving a test strip, whether an auto-send feature is enabled on the handheld medical device, determine whether the handheld medical device is paired with a mobile computing device, and selectively instruct a wireless transceiver to establish a wireless connection and communicate a glucose measurement and identifying information to the mobile computing device.
Roche Diabetes Care, Inc.

Condensed heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (i) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]..
Takeda Pharmaceutical Company Limited

Biaryl derivative as gpr120 agonist

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a gpr120 agonist, promoting glp-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.. .
Lg Chem, Ltd.

Risk-based control-to-range

Methods and systems are disclosed for determining a basal rate adjustment of insulin based on risk associated with a glucose state of a person with diabetes. A method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state.
Roche Diabetes Care, Inc.

Control-to-range aggressiveness

A method and system of determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes is provided. The method includes receiving, by at least one computing device, a signal representative of at least one glucose measurement; detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level; determining, by the at least one computing device, a current risk metric, the current risk metric indicating a risk of at least one of a hypoglycemic condition and a hyperglycemic condition of the person; and calculating, by the at least one computing device, an adjustment to a basal rate of a therapy delivery device based on the current risk metric and a control-to-range algorithm comprising at least one aggressiveness parameter..
Roche Diabetes Care, Inc.

Control-to-range failsafes

Methods and systems are disclosed for determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes. A method may include receiving, by at least one computing device, a signal representative of at least one glucose measurement and detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level.
Roche Diabetes Care, Inc.

Method for ameliorating and abating symptoms resulting from rheumatoid arthritis, fibromyalgia, and chronic pain of unknown origin

The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as als, ra, tremors/parkinson's disease, and ms, alzheimer's disease, als, guillain-barre syndrome, atherosclerosis, schizophrenia, tremors/parkinson's disease, senile dementia, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis west nile virus,, fibromyalgia, shingles, gout, migraine headaches, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from als, ra, ms, tremors/parkinson's disease, and prostate cancer and others realized immediate beneficial results with no side effects..
Honor C.w. M.d., Llc

Compositions and methods for decreasing blood glucagon levels

Disclosed are improved compositions and methods for decreasing blood glucagon levels. As disclosed herein, l-glutamine is a selective stimulator of α-cell proliferation generated when glucagon signaling is interrupted.
Vanderbilt University

Use of helminthostachys zeylanica, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases

Disclosed is a use of helminthostachys zeylanica, ugonins or compounds of formula (i) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.. .
National Research Institute Of Chinese Medicine, Ministry Of Health And Welfare

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-iv enzyme (“dp-iv inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-iv enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-iv enzyme is involved..
Merck Sharp & Dohme Corp.

Method of treating liver fibrosis

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms)..
Chemocentryx, Inc.

Compositions containing omega-3 oil and uses thereof

The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.

System for adjusting pressure locally on the skin and subcutaneous tissue

The invention relates to a system for adjusting pressure locally acting on the skin. Said system includes a set of adjacent modules distributed so as to form a layer.
Ecole Polytechnique Federale De Lausanne (epfl)

Electrode assembly

The present invention relates to an electrode assembly (eg a nanoelectrode assembly), to an electrochemical glucose biosensor comprising the electrode assembly and to an apparatus for combating (eg management of) diabetes mellitus which comprises the electrochemical glucose biosensor.. .
Nanoflex Limited

System and assessing quantities or sizes of lipoprotein particles from lipoprotein particle compositions

This application discloses methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and/or phospholipid content in the lipoprotein particles. Methods of treating a subject at increased risk for cardiovascular disease and/or cardiodiabetes are also disclosed..
True Health Ip Llc

Hepatocyte based insulin gene therapy for diabetes

A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′utr and lacks an hgh intron, wherein the second vector comprises an hgh intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′utr and lacks a promoter enhancer, wherein the third vector comprises an hgh intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′utr and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled..
Wisconsin Alumni Research Foundation

Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion

This invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like rna (shrna) compositions, such as microrna precursors (pre-mirna) and short interfering rnas (sirna), which are useful for treating human ageing related diseases, such as, but not limited, alzheimer's diseases, parkinson's diseases, osteoporosis, diabetes, and cancers.

Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity

The present invention provides pharmaceutical compositions formulated for direct delivery to the gi tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the gi tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition..
Circle 33 Llc

Methods and compositions to treat type-1 and type-2 diabetes

The present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating tlr2 and tlr4 genes together in cells capable of producing insulin and/or regenerating β cells, and providing the cells to a subject in need thereof.. .
Cornell University

Pyrazino[2,3-b]pyrazine mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway

Wherein r1-r4 are as defined herein, compositions comprising an effective amount of a heteroaryl compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a heteroaryl compound to a patient in need thereof.. .

A multi-state ratchet mechanism for drug injection devices

The present invention relates in a first aspect to a multi-state ratchet mechanism for a drug injection device. The multi-state ratchet mechanism comprises a ratchet gear member and a cooperating ratchet pawl member.
Novo Nordisk A/s

Cell-based composition and use thereof for treatment of diabetes and associated metabolic disorders and for amelioration of insulin resistance in pre-diabetes

The present invention relates to a cell-based composition comprising a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml. The cell-based composition is used in a form of medicament for treatment of diabetes and its associated metabolic disorders and complications..
Cytopeutics Sdn. Bhd.

Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient

Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University

Bromocriptine formulations

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes..
Veroscience Llc

Alpha-cell re-generation combined with conversion to beta cells

The present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with gaba or a gaba receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy.. .
Universite De Nice Sophia Antipolis-grand ChÂteau

Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions

Methods for identifying responders to agents that increase brain dopaminergic neuronal activity for the treatment of metabolic and cardiovascular disease and for treating elevated heart rate and metabolic disease or dysglycemia in subjects with type 2 diabetes.. .
Veroscience Llc

Anti-acth antibodies and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

New pyrazolopyrimidine derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutical Nv

New compounds as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

New pyrazole derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

Compounds and methods for activating the apoptotic arm of the unfolded protein response

N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the unfolded protein response are provides as is their use in the treatment of diseases such as diabetes, alzheimer's, parkinson's, hemophilia, lysosomal storage diseases and cancer.. .
Sanford-burnham Medical Research Institute

Pyrazole compounds

This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (metap2) and dipeptidyl peptidase-4 (dpp-4).
Eli Lilly And Company

Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.. .

Novel approach to treatment of hyperglycemia using a nanoparticle encapsulated peptide

The present invention relates to compositions and methods for treating or preventing hyperglycemia and diseases associated with hyperglycemia. In certain embodiments, the composition comprises a peptide having the amino acid sequence krscyk wherein the peptide consists of d-amino acids is useful in treating or preventing diabetes.
University Of Rochester

Methods for treating and/or limiting development of diabetes

The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.. .
Biocrine Ab

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. .
Boehringer Ingelheim International Gmbh

Salts and compositions useful for treating disease

The invention provides a combination or salt of lipoic acid and a compound of formula (i): the combinations and salts are useful for treating diabetes.. .
Regents Of The University Of Minnesota

Therapeutic compound and its application in repairing diabetes-related cardiac injuries

The present invention is related to a therapeutic compound and its application in repairing diabetes-related cardiac injuries, particularly with providing a therapeutic composition containing the epigallocatechin gallate (egcg) of green tea and the adipose-derived stem cells. The epigallocatechin gallate (egcg) of green tea can enhance the ability of the adipose-derived stem cells to repaired damaged tissue.
Numen Biotech Co., Ltd

Method of treating hyperglycemia

Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type i, ii diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto.
Center Laboratories, Inc.

Methods and systems for treating diabetes and related diseases and disorders

Systems, device and methods treat target tissue to provide a therapeutic benefit to the patient. A tissue treatment device comprises a tissue treatment element constructed and arranged to treat target tissue, such as duodenal mucosa tissue..
Fractyl Laboratories, Inc.

Method for treating diabetes and other glucose regulation disorders using stem cells

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing l-cells from a donor, obtaining stem cells from a patient, and culturing the l-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived l-cells (scdlc).
Incube Labs, Llc

Composition to induce bone marrow stem cell mobilization

A pharmaceutical composition to induce bone marrow stem cell mobilization from the bone marrow to peripheral blood in patients suffering from pathological conditions, such as diabetes, or subjected to treatments that impair cell mobilization, or in patients suffering from the so called “poor mobilizer” condition, includes at least one therapeutic agent that inhibits production and/or action of the human cytokine oncostatin m (osm), a macrophage derived factor, that prevents mobilization of stem cells.. .
Universitá Degli Studi Di Padova

Omefibrates for treating dyslipidemia and cardiovascular disease

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).. .
Jiva Pharma, Inc.

Satiation peptides for weight loss and altered taste sensitivity

The present application provides methods and compositions for aav-mediated delivery of pyy and glucagon-like peptide 1 or an analog thereof (e.g., exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of ex-4 and pyy peptides also are provided.
University Of Florida Research Foundation, Inc.

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Treatment of mild and moderate alzheimer's disease

The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“compound i”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of alzheimer's type, diabetes, insomnia, and other indications.
Vtv Therapeutics Llc

Methods for detecting gestational diabetes mellitus

The present invention relates to methods for diagnosing gestational diabetes mellitus (gdm) in a pregnant female.. .
Kantonsspital Aarau Ag

Methods and compositions for diagnosis and management of diabetes and metabolic syndrome

Described herein are assays, methods, and devices for diagnosing/prognosing diabetes, metabolic syndrome, pre-diabetic state and/or the early-onset of diabetes in a subject. The assays, methods, and devices described herein can be configured to detect one or more long-coding rnas in a sample from a subject..
The U.s. Government As Represented By The Departme Nt Of Veterans Affairs Office Of General Counsel

Alpha/beta-polypeptide analogs of glucagon-like peptide 1

Described herein are peptide analogs of glucagon-like peptide 1 (glp-1) that retain agonist activity, but are more resistant to proteolytic degradation than native glp-1. In the analogs, at least one α-amino acid found in the native glp-1 is replaced with a β-amino acid residue, which may or may not be cyclically constrained.
President And Fellows Of Harvard College

Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-n-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes

Disclosed are compounds, pharmaceutical compositions and methods for modulating aquaporin 9.. .
Apoglyx Ab

Novel heterocyclic derivatives and their use in the treatment of neurological disorders

In which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of alzheimer's disease or diabetes via inhibition of bace-1 or bace-2.. .

Novel pentadienoyl piperidine derivative and use thereof

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and blood glucose levels, improves a blood liver function index, and suppresses metabolic inflammation responses.
Snu R&db Foundation

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase iv (dpp iv) inhibitor or one or more biguanide antihyperglycaemic agent and a ppar agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes or type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions.
Cadila Healthcare Limited



Diabetes topics:
  • Immune Disorder
  • Autoimmune
  • Immune Disease
  • Immune Diseases
  • Autoimmune Disorder
  • Type 1 Diabetes
  • Autoimmune Disorders
  • Vascular Diseases
  • Antimicrobial
  • Cardiovascular
  • Inflammatory Disease
  • Antimicrobial Agent
  • Stem Cells
  • Human Embryonic Stem Cell
  • Embryonic Stem Cell


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Diabetes for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Diabetes with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.7122

    file did exist - file did put12147

    3 - 1 - 252